Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Fenobet - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Fenobet

Approved

STANDARD

Fenobet

Cooper Pharma Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: eb51f7ba32eba10f
Company: Cooper Pharma Limited
Type: Standard

Approval Details

Approval Id: eb51f7ba32eba10f
Drug Approval Philippines Name: Fenobet
Product Name: Fenobet
Registration Number: DRP-6162-02
Brand Name: Fenobet
Generic Name: Fenofibrate
Dosage Form: Capsule
Dosage Strength: 200 mg
Manufacturer: Cooper Pharma Limited
Importer: Suhitas Pharmaceuticals Inc
Distributor: Better Option Pharmaceuticals Inc
Issuance Date: 27 January 2023
Expiry Date: 10 February 2028
Pharmacologic Category: Lipid Modifying Agents (Fibrates)
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

eb51f7ba32eba10f

Type

Standard

Back to Philippines FDA Approvals